EUVIMEDEUVIMED entdecken
Systematische Übersicht

KCNQ2-Related Epilepsy: Genotype–Phenotype Relationship with Tailored Antiseizure Medication (ASM)—A Systematic Review

Raffaele Falsaperla, Roberta Criscione, Carla Cimino, Francesco Pisani, Martino Ruggieri

Neuropediatrics · 01.10.2023 · 54 (05) · 297-307

DOI: 10.1055/a-2060-4576 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neuropediatrics, erschienen am 01.10.2023. Verfasst von Raffaele Falsaperla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal Intensive Care Unit and Neonatal Accompaniment Unit, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco", San Marco Hospital,…. Hauptthemen laut MEDLINE: KCNQ2 Potassium Channel, Epilepsy, Benign Neonatal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autosomal dominant mutations of the KCNQ2 gene can cause two epileptic disorders: benign familial neonatal seizures (BFNS) and developmental epileptic encephalopathy (DEE). This systematic review aims to identify the best reported therapy for these patients, relating to phenotype, neurodevelopmental outcome, and an eventual correlation between phenotype and genotype.

Methods

We searched on PubMed using the search terms “KCNQ2” AND “therapy” and “KCNQ2” AND “treatment”; we found 304 articles. Of these, 29 met our criteria. We collected the data from 194 patients. All 29 articles were retrospective studies.

Results

In all, 104 patients were classified as DEE and 90 as BFNS. After treatment began, 95% of BFNS patients became seizure free, whereas the seizures stopped only in 73% of those with DEE. Phenobarbital and sodium channel blockers were the most used treatment in BFNS. Most of the DEE patients (95%) needed polytherapy for seizure control and even that did not prevent subsequent developmental impairment (77%). Missense mutations were discovered in 96% of DEE patients; these were less common in BFNS (50%), followed by large deletion (16%), truncation (16%), splice donor site (10%), and frameshift (7%).

Conclusion

Phenobarbital or carbamazepine appears to be the most effective antiseizure medication for children with a “benign” variant. On the contrary, polytherapy is often needed for DEE patients, even if it does not seem to improve neurological outcomes. In DEE patients, most mutations were located in S4 and S6 helix, which could serve as a potential target for the development of more specific treatment in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KCNQ2 Potassium ChannelEpilepsy, Benign NeonatalChildInfant, NewbornHumansRetrospective StudiesMutationSeizuresPhenotypeGenotypePhenobarbital

Substanzen

KCNQ2 Potassium ChannelPhenobarbital

Autor:innen und Institutionen

  • Neonatal Intensive Care Unit and Neonatal Accompaniment Unit, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco", San Marco Hospital, University of Catania, Catania, Italy.
  • Unit of Clinical Paediatrics, Azienda Ospedaliero-Universitaria Policlinico, "Rodolico-San Marco", San Marco Hospital, Catania, Italy.
  • Neonatal Intensive Care Unit and Neonatal Accompaniment Unit, Azienda Ospedaliero-Universitaria Policlinico "Rodolico-San Marco", Postgraduate Training Program in Pediatrics, University of Catania, Catania, Italy.
  • Child Neuropsychiatry Unit, Human Neuroscience Department, Sapienza University of Rome, Italy.
  • Unit of Clinical Pediatrics, Department of Clinical and Experimental Medicine, University of Catania, AOU "Policlinico", PO "G. Rodolico", Catania, Italy.

Zitieren

APA

Falsaperla, R., Criscione, R., Cimino, C., Pisani, F., & Ruggieri, M. (2023). KCNQ2-Related Epilepsy: Genotype–Phenotype Relationship with Tailored Antiseizure Medication (ASM)—A Systematic Review. Neuropediatrics, 54(05), 297-307. https://doi.org/10.1055/a-2060-4576

Vancouver

Falsaperla R, Criscione R, Cimino C, Pisani F, Ruggieri M. KCNQ2-Related Epilepsy: Genotype–Phenotype Relationship with Tailored Antiseizure Medication (ASM)—A Systematic Review. Neuropediatrics. 2023;54(05):297-307. doi:10.1055/a-2060-4576

BibTeX
@article{Falsaperla2023,
  author = {Falsaperla, Raffaele and Criscione, Roberta and Cimino, Carla and Pisani, Francesco and Ruggieri, Martino},
  title = {KCNQ2-Related Epilepsy: Genotype–Phenotype Relationship with Tailored Antiseizure Medication (ASM)—A Systematic Review},
  journal = {Neuropediatrics},
  year = {2023},
  volume = {54},
  number = {05},
  pages = {297--307},
  doi = {10.1055/a-2060-4576}
}
Kostenlos starten →